ConductScience.org, home

Paper36901764

A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition.

Barrios-Bernal P and 4 others. Int J Mol Sci, 2023. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition. Papers, record 36901764. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36901764

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.69
iCite
Revised in PubMed
2026-01-27
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Barrios-Bernal PPedro
2Lucio-Lozada JJoséhttps://orcid.org/0000-0002-6881-4794
3Ramos-Ramírez MMaritza
4Hernández-Pedro NNorma
5Arrieta OOscarhttps://orcid.org/0000-0002-1164-3779

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
MetforminMajor topic
Humans
Apoptosis
Cell Line
Mutation
Proto-Oncogene Proteins c-akt
Proto-Oncogene Proteins p21(ras)
Ribosomal Protein S6 Kinases, 70-kDa
TOR Serine-Threonine Kinases
Piperazines
Pyridines
Pyrimidines

Source PubMed

Download CSV of topics

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133294856Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.Cell Rep Med2020https://conductscience.org/library/papers/33294856PubMed
227519177Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer.BMC Cancer2016https://conductscience.org/library/papers/27519177PubMed
335402614Gypenoside-Induced Apoptosis via the PI3K/AKT/mTOR Signaling Pathway in Bladder Cancer.Biomed Res Int2022https://conductscience.org/library/papers/35402614PubMed
426359221Metformin: risk-benefit profile with a focus on cancer.Expert Opin Drug Saf2015https://conductscience.org/library/papers/26359221PubMed
521540236Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.Cancer Res2011https://conductscience.org/library/papers/21540236PubMed
633022831KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC).Thorac Cancer2020https://conductscience.org/library/papers/33022831PubMed
723362830Metformin induces cytotoxicity by down-regulating thymidine phosphorylase and excision repair cross-complementation 1 expression in non-small cell lung cancer cells.Basic Clin Pharmacol Toxicol2013https://conductscience.org/library/papers/23362830PubMed
835337178Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial-Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells.Pharmaceuticals (Basel)2022https://conductscience.org/library/papers/35337178PubMed
926673006Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.Oncotarget2016https://conductscience.org/library/papers/26673006PubMed
1034244683Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment.Nat Rev Cancer2021https://conductscience.org/library/papers/34244683PubMed
1131486833
Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
JAMA Oncol2019https://conductscience.org/library/papers/31486833PubMed
1231276344Mutational profile by targeted next generation sequencing of non-small cell lung cancer in the Mexican population.Salud Publica Mex2019https://conductscience.org/library/papers/31276344PubMed
1334675734Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer.Lung Cancer (Auckl)2021https://conductscience.org/library/papers/34675734PubMed
1432540954AMG 510 Shows Activity beyond NSCLC.Cancer Discov2020https://conductscience.org/library/papers/32540954PubMed
1528481268Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies.Cancers (Basel)2017https://conductscience.org/library/papers/28481268PubMed
1632750661KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.Cancer Treat Res Commun2020https://conductscience.org/library/papers/32750661PubMed
1726847819Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.Mol Med Rep2016https://conductscience.org/library/papers/26847819PubMed
1823707609Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways.Toxicol Appl Pharmacol2013https://conductscience.org/library/papers/23707609PubMed
1932955176KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.N Engl J Med2020https://conductscience.org/library/papers/32955176PubMed
2030327306KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.Clin Cancer Res2019https://conductscience.org/library/papers/30327306PubMed

See all 35 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42240478Targeting GSTZ1 Sensitizes KRASG12C-Mutant Lung Cancer Cells by Overcoming Glutathione and Glycolysis Pathway Rewiring.Cancer Res Commun2026https://conductscience.org/library/papers/42240478PubMed
41824068The clinicopathologic characteristics and outcomes of uncommon KRAS mutations in patients with non-small cell lung cancer.Virchows Arch2026https://conductscience.org/library/papers/41824068PubMed
40756996Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma.Front Pharmacol2025https://conductscience.org/library/papers/40756996PubMed
39202556Metformin in Chemoprevention of Lung Cancer: A Retrospective Population-Based Cohort Study in Lithuania.Medicina (Kaunas)2024https://conductscience.org/library/papers/39202556PubMed
37627169Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib.Cancers (Basel)2023https://conductscience.org/library/papers/37627169PubMed

Download CSV of cited by

Genes20

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
ANXA5308PubTator's text mininghttps://conductscience.org/library/genes/308NCBI Gene
BAX581PubTator's text mininghttps://conductscience.org/library/genes/581NCBI Gene
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
BCL2L1598PubTator's text mininghttps://conductscience.org/library/genes/598NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
GAPDH2597PubTator's text mininghttps://conductscience.org/library/genes/2597NCBI Gene
KRAS3845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene
MAP2K75609PubTator's text mininghttps://conductscience.org/library/genes/5609NCBI Gene
MAPK15594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
PRKAA25563PubTator's text mininghttps://conductscience.org/library/genes/5563NCBI Gene
RAF15894PubTator's text mininghttps://conductscience.org/library/genes/5894NCBI Gene
RHEB6009PubTator's text mininghttps://conductscience.org/library/genes/6009NCBI Gene
RPS6KB16198PubTator's text mininghttps://conductscience.org/library/genes/6198NCBI Gene
STK116794PubTator's text mininghttps://conductscience.org/library/genes/6794NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene
ZHX222882PubTator's text mininghttps://conductscience.org/library/genes/22882NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36901764

GET https://conductscience.org/api/papers/v1/36901764/references?page=2